The protracted development of antibiotic ceftobiprole has left Swiss biotech firm Basilea Pharmaceutica (SIX: BSLN) under a cloud of investor disillusionment, say analysts at Edison Investment Research.
Realizing the value on Toctino (alitretinoin) gives the company financial flexibility to be opportunistic in the anti-infectives and oncology fields. Ceftobiprole’s US launch remains uncertain. However, progress is being made in the antifungal area (Phase III data due 2013), and in two Phase I compounds, the analysts note.
Balance sheet strengthened by Toctino deal
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze